• Restructure
  • About Purdue
    • Ethics and Compliance
    • Locations & Operations
    • Public Policies
  • News & Media
    • New Media Resources
    • Perspectives
    • Media Contacts
  • Careers at Purdue
    • What We Offer You
    • How to Apply
  • Contact Us
Purdue Pharma
  • Healthcare Professionals
    • Purdue Products
    • Patient Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Clinical Trials
  • Patients & Caregivers
    • Medicines From Purdue
    • Cost Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Expanded Access Program
  • Addressing the Crisis
    • Public Policies
    • Strong Track Record
    • Ongoing Efforts
    • What We’re Doing Now
    • Perspectives
  • Partnering
  • Corporate Social Responsibility
    • Grants & Giving
Select Page

Purdue Pharma Urges Accuracy in Communications on Abuse-Deterrent Formulations of Opioids

Sep 24, 2018 | News

STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is...

Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference

Sep 6, 2018 | News

News and Media Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference Results Show Successful Uptake of Technology and Increased Patient‐Provider Communication STAMFORD, Conn., and...

Purdue Pharma L.P. to Present Data from Three Research Studies at PAINWeek® 2018 Annual Conference

Sep 6, 2018 | News

News and Media Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual Conference Studies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September...

Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive, Over-the-Counter, Life-Saving Naloxone in the United States

Sep 5, 2018 | News

STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced that Purdue is providing a $3.42 million grant to Harm Reduction Therapeutics to advance the...

Recent Posts

  • Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement
  • The Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide
  • Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis
  • Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
  • Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting

Archives

  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • October 2018
  • September 2018
  • August 2018
  • February 2018
  • January 2018

Categories

  • News
Purdue, as used in this site, refers to Purdue Pharma L.P. and its subsidiaries, which include Avrio Health L.P., Imbrium Therapeutics L.P., Adlon Therapeutics L.P. and Greenfield BioVentures L.P., Rhodes Pharmaceuticals L.P., Rhodes Technologies, Purdue Pharmaceuticals L.P., and Purdue Pharma Manufacturing L.P.